NHSA Releases 2026 NRDL Update Adding 107 Drugs Including Million‑Yuan CAR‑T Therapies – Ninth List Adjustment Since the Agency’s Establishment
China's National Healthcare Security Administration (NHSA) released the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work‑Related Injury Insurance (NRDL) and the Commercial Health Insurance Innovative Drug List…
BeOne Medicines Opens Shanghai Innovation Center – A 55,855 m² Self‑Built R&D Hub Purpose‑Built for AI‑Driven Antibody Discovery and Next‑Generation ADCs
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced the official opening of its Shanghai Innovation Center, a wholly self‑built research and development campus that will serve as one of the global biotech's key hubs for early‑stage drug discovery.…
Where biopharma's biggest deals take shape!
Ascentage Pharma Ties Up With China’s Big Three Distributors – Strategic Channel Agreements to Accelerate Lisaftoclax, China’s First Domestically Developed Bcl‑2 Inhibitor
Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) announced that it has formally signed strategic channel cooperation agreements with three leading national pharmaceutical distributors – Sinopharm Group, Shanghai Pharma Holding, and China…
NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…
